Johnson & Johnson agreed to acquire Ollin Biosciences for up to $3.3 billion, positioning the deal around OLN324, a late-stage bispecific antibody in ophthalmology aimed at VEGF/Ang2-driven disease. The companies said the acquisition is intended to create a growth platform in eye care for an area with persistent unmet need. The transaction includes Blackstone Life Sciences’ $750 million support for Phase 3 development of OLN324 in wet age-related macular degeneration and diabetic macular edema. Analysts highlighted potential market competition against Roche’s Vabysmo and Eylea, with the key question focused on whether OLN324 delivers meaningful differentiation in efficacy and durability in a crowded therapeutic class. Regulatory and manufacturing execution will be the near-term focus for investors, since Phase 3 program momentum and topline readouts can materially affect the valuation trajectory of the asset and the strategic rationale of J&J’s expansion beyond its historically device-heavy ophthalmology footprint.
Get the Daily Brief